



Supplementary Materials


A




B



Supplementary Figure S1. Vector construction. (A). Schematic diagram of the construction of the pLV/Puro-EF1α-eGFP vector. (B). Schematic diagram of the construction of the pLV/Puro-EF1α-CCR2-IRES-eGFP vector.



Supplementary Figure S2. CCR2 overexpression had no significant effects on the biological characteristics of HUC-MSCs. (A) Morphological observation of the HUC-MSCs^{Ctrl} and HUC-MSCs^{CCR2} under a fluorescence microscope, scale bar = 200 μ m. (B) Osteogenic adipogenesis induction experiments for the HUC-MSCs^{Ctrl} and HUC-MSCs^{CCR2}, scale bar = 50 μ m. (C) Flow cytometric detection of the HUC-MSC-specific markers CD13, CD29, CD44, CD73, CD34, CD45, CD90, CD105, and HLA-DR in the HUC-MSCs^{Ctrl} and HUC-MSCs^{CCR2}.



Supplementary Figure S3. Establishment of tMCAO was confirmed by mNSS behavioral test and TTC staining at 1 day after surgery. (A) Left hemiplegia in rat. (B) Right cerebral infarction in brain from rat.